*Promoted by Legends Media

XRTX is a Biotech Blockbuster that Rallied 100% in Just a Few Weeks

… It Just Flashed a DOUBLE “GO” Signal!

While the overall market continues to be undecided on the next direction, a lot of smaller stocks have been in full-on “rally mode” lately.

Just like the small stock I revisited with you yesterday that made a whopping 18% move higher during yesterday’s trading session?

That stock is now up over 350% from the lows just a few months ago!

But, do you hear anyone on TV talking about moves like these?  Of course not!

They want you to think the only opportunities out there are with large-cap tech stocks.

I won’t argue that the stories behind tech giants like NVDA, MSFT and even SMCI are very good right now.

The problem is that those stocks have already made huge runs.  Do you really think they have a lot more upside from here?

I would rather focus on smaller stocks that have a lot of potential ahead of them.

That brings me to today’s top idea I want you to start looking into immediately…

Pull up XORTX Therapeutics (XRTX) on your platform right away.

Just like I showed you yesterday, this is another perfect “Gamma Trigger” type of set up we have right this moment.

If you look at the price chart below, you’ll see that in late February XRTX started to regain upward momentum above the 20-hour line and we got not one… but TWO “GO” signals.

Folks, how many times have we seen charts like this?

By now you know what a powerful trigger this can be.  In this case, the stock rallied from $2.50 to over $7.00 in around two weeks’ time.

That was a more than 180% move right under the noses of most traders.

Ok, so you missed that move, but it proves the powerful potential that XRTX can have.

Now, look at where the stock is right now. ☝️

You can clearly see it right?

After a pause in the uptrend, XRTX is now back above the 20-hour line and we have another DOUBLE “GO” signal staring us right in the face.

For me, it really doesn’t get much better than that.  I call these “cupcake” setups. 🧁

Now, do they always work or make a huge move?  Of course not. Nothing is guaranteed when it comes to trading.

All I can do as a trader is find the best setups I can, and then approach them with a well-thought-out, and responsible game plan, and I hope you do the same thing.

My goal is always to keep my losses to a minimum, but let my winners ride until the trend tells me to get out.

Just like the trade idea yesterday that netted 18% by the end of the day, or the ERX trade I closed out for 100%, or the massive move on QQQ’s I told you about that I barely missed on Tuesday…

XRTX is one of those opportunities that you really need to take a close look at right away.

The technicals are stellar, but you should also look at the core business of XRTX

XORTX Therapeutics Inc. (XRTX) is a late-stage pharmaceutical company focused on kidney diseases with medical needs that are largely unmet. 

The company’s CEO is pharma all-star CEO Allen W. Davidoff, PhD, who was the co-founder and Chief Scientific Officer at Stem Cell Therapeutics Corp. which merged with Trillium Therapeutics before being acquired by Pfizer for $2.2 billion.

Dr. Davidoff was also responsible for the development of oxypurinol, forms of which are XRTX’s lead assets.

Right now, the leading indication for the drug is Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening genetic disease affecting 160,000 patients in the US…

A majority of those patients will wind up needing dialysis or kidney transplantation. 

As of now, there’s only one drug — JYNARQUE® — on the market to treat ADPKD, and it’s not tolerated by 95% of patients. It features a “black box warning” for “risk of serious liver injury.”

Nevertheless, sales of the drug reached $962 million in 2022 thanks to its ~$156,000/year price tag.

Clearly, something new is needed, and there’s a big market for it.

Right now, XRTX is on the path to accelerated FDA approval for its ADPDK treatment, and has received an Orphan Drug Designation for the same.

You can read more about the science behind oxypurinol and ADPDK on the company’s website here, but for our purposes, the company is reporting “potential for early revenue in 2026 just in time to replace [JYNARQUE®].”

XRTX is currently preparing to enter a Phase III trial for the ADPDK treatment, and reports a “clear focus on XRx-008 program for ADPKD with a $1.0-1.8 Billion USD per year revenue potential for XRTX in the US alone.”

The PKD Foundation — the leading polycystic kidney disease foundation in the world — has recognized XRTX “as a leader in advancing the development of treatments for progressive kidney disease.”

Apart from its work on ADPDK, the company is also testing its therapies for cases of Type 2 Diabetic Nephropathy (preclinical stage) and Acute Kidney Injury (Phase II stage), especially as it relates to COVID-19 infections.

XTRX says it has a “strong cash position of $5.2 Million” giving it a “runway for 14 months” as of this month.

This is a really exciting opportunity, and you should poke around on Google to see what you find.  Always do your own due diligence, and of course, always approach your trading in a responsible manner. Never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: XRTX has been on an absolute tear for the last several weeks.  With all of the positive business developments we have seen the stock rally over 100% from the lows recently.  With a strong “double GO signal” fired yesterday, this is a time-sensitive stock that you should look into immediately.

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Raging Bull has been paid seventeen thousand five hundred dollars from Legends Media who was compensated by a third party not affiliated with the Company for advertising XORTX Therapeutics Inc for a one day marketing program on March 14, 2024. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of XORTX Therapeutics Inc, increased trading volume, and possibly an increased share price of XORTX Therapeutics Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in XORTX Therapeutics Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. 

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.